Sign in

MetLife, Inc. MET

Price 99.2 USD
as of 2026-09-05
54/100
Constructive
Quality43
Growth38
Balance-sheet strength39
Valuation70
Momentum78
Income76

Composite 54/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Growth ranks 38/100 — a slight mark against it.

Case for

Momentum ranks 78/100 — a strong point in its favour. Income ranks 76/100 — a strong point in its favour. Valuation ranks 70/100 — a moderate point in its favour.

Case against

Growth ranks 38/100 — a slight mark against it. Balance-sheet strength ranks 39/100 — a slight mark against it. Quality ranks 43/100 — a slight mark against it.

What the company does MetLife provides life, health, disability, accident, and annuity products across six global segments. It also offers employee benefits, pension risk transfers, and asset management services to corporations and individuals.

Key financials MetLife posts ROE 13.1%, net margin 4.6%, and revenue/EPS growth of 10.5%/5.8%. Debt/equity is 1.80 with a current ratio of 2.03; dividend yield is 2.5% at a 24% payout.

Stock health Sideravia scores MetLife Weak quality (50.7) but attractive valuation (67.3) and strong momentum (74.5). Recent 12-month return is 27.62% with RSI(14) at 58.50.

Price vs fair value MetLife trades at a discount of 7.40% versus the analyst mean target of 103.88. - Analysts highlight open questions from the Q2 2026 earnings call (Motley Fool) - StockStory flags “Top 5 Analyst Questions” post-results - StockStory labels MetLife among “3 Inflated Stocks with Open Questions”

Looking forward Forward P/E of 10.66 and PEG of 0.14 suggest valuation support, but weak quality and high leverage warrant caution. Momentum remains positive, offsetting margin pressures.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.